The lack of increases in circulating endothelial progenitor cell as a negative predictor for pathological response to neoadjuvant chemotherapy in breast cancer patients.
The lack of increases in circulating endothelial progenitor cell as a negative predictor for pathological response to neoadjuvant chemotherapy in breast cancer patients.
复制标题
DOI：
10.1038/s41698-017-0006-1
复制
发表时间：
2017
影响因子：
7.9
通讯作者：
Toi M
中科院分区：
文献类型：
--
作者：
Tanaka S;Ueno T;Ishiguro H;Morita S;Toi M
循环内皮祖细胞是血管生成的潜在替代标志物。新辅助化疗期间循环内皮祖细胞计数的变化知之甚少。我们的目标是揭示乳腺癌患者CEP计数的变化与新辅助化疗反应的关系。我们采用四色流式细胞术检测了57例接受新辅助化疗（5-氟尿嘧啶+表阿霉素+环磷酰胺（FEC）、多西他赛+环磷酰胺（TC）、顺铂+多西他赛（TP））的乳腺癌患者的循环内皮祖细胞（CD 31 + CD 34 + CD 133 + CD 45 dim）数量。基线循环内皮祖细胞计数与临床和病理背景因素无显著差异。化疗开始后循环内皮祖细胞计数增加（第1周期前与第2周期前，p = 0.0035;第1周期前与第4周期前，p = 0.047）。从第1周期前至第2周期前循环内皮祖细胞计数的增加与pCR相关（χ 2检验p = 0.013）。一项多变量分析（包括亚型和临床应答）显示，从第1个周期前至第2个周期前循环内皮祖细胞缺乏增加是pCR的独立阴性预测因子（p = 0.002）。我们的数据表明，循环内皮祖细胞计数的改变与治疗反应有关。循环内皮祖细胞计数可能是监测化疗反应的有用生物标志物。乳腺癌患者在术前化疗后，如果循环内皮祖细胞（CEP）的数量增加，效果会更好。由东京杏林大学医学院的Takayuki Ueno领导的日本研究小组研究了57名接受新辅助化疗以缩小手术前肿瘤大小的女性。研究人员在化疗前和化疗期间测量了CEPs细胞的数量，CEPs细胞来自骨髓，可以帮助肿瘤周围建立新的血管。他们发现总CEP计数和治疗反应之间没有联系。然而，化疗周期之间CEP数字上升的患者有更好的结果。作者认为，CEP计数可作为预测新辅助化疗反应的诊断工具，尽管需要更大规模的研究来证实他们的初步发现
Circulating endothelial progenitor cells are a potential surrogate marker for angiogenesis. Little is known about the alteration of circulating endothelial progenitor cell counts during neoadjuvant chemotherapy. Our goal was to reveal the alteration in CEP counts in association with response to neoadjuvant chemotherapy in patients with breast cancer. We measured the number of circulating endothelial progenitor cells (CD31+CD34+CD133+CD45dim) by four-color flow cytometry using blood samples from 57 patients with breast cancer who received neoadjuvant chemotherapy (5-fluorouracil + epirubicin + cyclophosphamide (FEC), docetaxel + cyclophosphamide (TC), cisplatin + docetaxel (TP)). There was no significant difference in the baseline circulating endothelial progenitor cell counts with respect to the clinical and pathological background factors. Circulating endothelial progenitor cell counts increased after the initiation of chemotherapy (pre-1st vs. pre-2nd cycle, p = 0.0035; pre-1st vs. pre-4th cycle, p = 0.047). An increase of circulating endothelial progenitor cell counts from pre-1st to pre-2nd cycle was associated with pCR (p = 0.013 for χ 2 test). A multivariate analysis, including subtype, and clinical response showed that the lack of circulating endothelial progenitor cell increases from pre-1st to pre-2nd cycle was an independent negative predictor of pCR (p = 0.002). Our data suggest that alterations in circulating endothelial progenitor cell counts are associated with treatment response. The circulating endothelial progenitor cell count could be a useful biomarker for monitoring chemotherapeutic response. Breast cancer patients do better after preoperative chemotherapy if their numbers of circulating endothelial progenitor cells (CEPs) go up. A team from Japan led by Takayuki Ueno from the Kyorin University School of Medicine in Tokyo studied 57 women who underwent neoadjuvant chemotherapy to shrink the size of their tumors before surgery. The researchers measured the number of CEPs—cells that derive from the bone marrow and can help build new blood vessels around tumors—both before and during chemotherapy. They found no link between overall CEP counts and treatment response. However, patients whose CEP numbers went up between cycles of chemotherapy had better outcomes. The authors suggest that CEP counts could be used as a diagnostic tool for predicting responses to neoadjuvant chemotherapy, although larger studies are needed to confirm their initial findings
登录
查看更多内容
影响因子：
56.9
作者：
Asahara, T;Murohara, T;Isner, JM
通讯作者：
Isner, JM
影响因子：
14.8
作者：
Duda, Dan G.;Cohen, Kenneth S.;Jain, Rakesh K.
通讯作者：
Jain, Rakesh K.
影响因子：
11.4
作者：
Asahara, T;Takahashi, T;Isner, JM
通讯作者：
Isner, JM
影响因子：
20.3
作者：
Heeschen, C;Aicher, A;Dimmeler, S
通讯作者：
Dimmeler, S
影响因子：
6.1
作者：
Murata, T;Yamawaki, H;Karaki, H
通讯作者：
Karaki, H